Related Experiment Video
Updated: Jul 15, 2026
08:02
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
Modulation of in vivo 3-deoxyglucosone levels
1Departments of Radiology and Biomedical Engineering, Columbia University, New York, NY, U.S.A. trb11@columbia.edu
Biochemical Society Transactions
|December 4, 2003
Summary
Fructoseamine-3-kinase (F3K) produces 3-deoxyglucosone (3DG). Inhibiting F3K lowers 3DG in diabetic rats, suggesting F3K is a therapeutic target for diabetic complications and 3DG-related diseases.
Area of Science:
- Biochemistry
- Metabolic pathways
- Diabetic complications
Background:
- Fructoselysine 3-phosphate is synthesized by fructoseamine-3-kinase (F3K) from fructoselysine and ATP.
- F3K activity leads to the formation of 3-deoxyglucosone (3DG), a key metabolite implicated in diabetic complications.
- The F3K pathway is a major contributor to in vivo 3DG production.
Purpose of the Study:
- To investigate the role of F3K in 3DG production.
- To evaluate the therapeutic potential of modulating F3K activity for diabetic complications.
- To assess the pathological consequences of elevated 3DG levels.
Main Methods:
- In vivo inhibition of F3K using substrate analogues.
- Stimulation of the F3K pathway by dietary glycated casein.
- Assessment of 3DG levels in plasma and kidney tubules.
- Evaluation of pathological effects in Eker rats and rat birth rates.
Main Results:
- F3K inhibitors reduced plasma 3DG levels by approximately 50% in diabetic rats.
- Stimulation of F3K increased plasma 3DG 10-20 fold and kidney 3DG 3-fold.
- Elevated 3DG levels resulted in a 3-fold increase in kidney lesions in Eker rats.
- Increased 3DG significantly reduced birth rates in Fischer 344 and Sprague-Dawley rats.
Conclusions:
- Inhibition of F3K is a promising therapeutic strategy for diabetic complications.
- Modulating F3K activity offers a potential approach to manage 3DG-dependent pathologies.
- The F3K pathway plays a critical role in the pathogenesis of diabetic complications and other diseases.
Related Concept Videos
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...